467.05

-1.1%↓

SANES

10.262

+0.55%↑

SAF

272.1

+0.67%↑

BBVA

18.665

+0.76%↑

BNP

89.84

+0.99%↑

467.05

-1.1%↓

SANES

10.262

+0.55%↑

SAF

272.1

+0.67%↑

BBVA

18.665

+0.76%↑

BNP

89.84

+0.99%↑

467.05

-1.1%↓

SANES

10.262

+0.55%↑

SAF

272.1

+0.67%↑

BBVA

18.665

+0.76%↑

BNP

89.84

+0.99%↑

467.05

-1.1%↓

SANES

10.262

+0.55%↑

SAF

272.1

+0.67%↑

BBVA

18.665

+0.76%↑

BNP

89.84

+0.99%↑

467.05

-1.1%↓

SANES

10.262

+0.55%↑

SAF

272.1

+0.67%↑

BBVA

18.665

+0.76%↑

BNP

89.84

+0.99%↑

Home・Akcijų sąrašas・AB Science SA

AB Science SA

Uždarymo kaina

1.156 1.94

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.134

Max

1.156

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-5.2M
Pardavimai	515K
Pelno marža	-1,005.243
Darbuotojai	36
EBITDA	-2.5M

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-11

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	77M
Ankstesnė atidarymo kaina	-0.78
Ankstesnė uždarymo kaina	1.156

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

1.426 / 1.448 Palaikymas ir pasipriešinimas

AB Science SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-26 21:14; UTC

Svarbiausios naujienos

Week Ahead for FX, Bonds: Major Central Bank Meetings Due as Middle East Conflict Continues

2026-04-26 21:14; UTC

Svarbiausios naujienos

Week Ahead for FX, Bonds: Major Central Bank -2-

2026-04-24 19:19; UTC

Įsigijimai, susijungimai, perėmimai

Intertek Group Rejects EQT's Revised Offer

2026-04-26 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise After U.S. Tech Gains -- Market Talk

2026-04-26 23:44; UTC

Uždarbis

Sinopharm 1Q Net CNY1.41B Vs. Net CNY1.46B >1099.HK

2026-04-26 23:44; UTC

Uždarbis

Sinopharm 1Q Rev CNY140.77B Vs. CNY141.66B >1099.HK

2026-04-26 23:36; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Falls Amid Dollar's Strength -- Market Talk

2026-04-26 23:33; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Rises Amid Ongoing Middle East Tensions -- Market Talk

2026-04-26 05:12; UTC

Uždarbis

Citic Securities: Results Also Aided by Higher Income from Brokerage, Income Banking Business >6030.HK

2026-04-26 05:12; UTC

Uždarbis

Citic Securities: Increase in Net Interest Income Supported Results >6030.HK

2026-04-26 05:12; UTC

Uždarbis

Citic Securities 1Q Rev CNY23.16B Vs. CNY16.43B >6030.HK

2026-04-26 05:12; UTC

Uždarbis

Citic Securities 1Q Net CNY10.22B Vs. Net CNY6.61B >6030.HK

2026-04-24 23:37; UTC

Įsigijimai, susijungimai, perėmimai

Scoring the Cook Era -- Barrons.com

2026-04-24 20:51; UTC

Įsigijimai, susijungimai, perėmimai

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

2026-04-24 20:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Financial Services Roundup: Market Talk

2026-04-24 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-04-24 20:39; UTC

Įsigijimai, susijungimai, perėmimai

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

2026-04-24 20:09; UTC

Uždarbis

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

2026-04-24 19:48; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

2026-04-24 19:25; UTC

Įsigijimai, susijungimai, perėmimai

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

2026-04-24 19:25; UTC

Įsigijimai, susijungimai, perėmimai

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

2026-04-24 19:22; UTC

Uždarbis

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

2026-04-24 19:06; UTC

Uždarbis

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

2026-04-24 19:05; UTC

Rinkos pokalbiai

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

2026-04-24 18:30; UTC

Įsigijimai, susijungimai, perėmimai

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

2026-04-24 18:28; UTC

Įsigijimai, susijungimai, perėmimai

Intertek Rejects Revised EQT Offer

2026-04-24 18:12; UTC

Rinkos pokalbiai

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

2026-04-24 18:06; UTC

Rinkos pokalbiai

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

2026-04-24 17:42; UTC

Uždarbis

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

2026-04-24 17:28; UTC

Uždarbis

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

AB Science SA Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių AB Science SA akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.426 / 1.448Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę AB Science SA

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.